revakinagene taroretcel-lwey - QuickHealthLife

QuickHealthLife

QuickHealthLife

Latest Medical News

2 Min Read

MacTel, ENCELTO implant, MacTel treatment, macular telangiectasia type 2, revakinagene taroretcel-lwey, CNTF for vision loss, FDA-approved MacTel therapy, neuroprotective retinal implant, ENCELTO clinical trials, slow vision loss, retinal degeneration treatment, , ENCELTO implant, MacTel treatment, macular telangiectasia type 2, revakinagene taroretcel-lwey, CNTF for vision loss, FDA-approved MacTel therapy, neuroprotective retinal implant, ENCELTO clinical trials, slow vision loss, retinal degeneration treatment,

onApril 28, 2026

First FDA-Approved ENCELTO Implant for MacTel: The Future of Retinal Disease Treatment

For the first time, patients with macular telangiectasia type 2 (MacTel) have an FDA-approved treatment that can slow vision loss. The ENCELTO…